JP2005511663A - 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用 - Google Patents

癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用 Download PDF

Info

Publication number
JP2005511663A
JP2005511663A JP2003548949A JP2003548949A JP2005511663A JP 2005511663 A JP2005511663 A JP 2005511663A JP 2003548949 A JP2003548949 A JP 2003548949A JP 2003548949 A JP2003548949 A JP 2003548949A JP 2005511663 A JP2005511663 A JP 2005511663A
Authority
JP
Japan
Prior art keywords
administered
amount
day
twice
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003548949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511663A5 (enExample
Inventor
デービッド エル． カットラー，
マイケル エル． メイヤーズ，
チャールズ バウム，
サラ エル． ザッコネン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005511663A publication Critical patent/JP2005511663A/ja
Publication of JP2005511663A5 publication Critical patent/JP2005511663A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003548949A 2001-11-30 2002-11-25 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用 Withdrawn JP2005511663A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (2)

Publication Number Publication Date
JP2005511663A true JP2005511663A (ja) 2005-04-28
JP2005511663A5 JP2005511663A5 (enExample) 2006-01-05

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003548949A Withdrawn JP2005511663A (ja) 2001-11-30 2002-11-25 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用

Country Status (13)

Country Link
US (2) US20030185831A1 (enExample)
EP (1) EP1448268A2 (enExample)
JP (1) JP2005511663A (enExample)
CN (2) CN1617755A (enExample)
AU (1) AU2002352941A1 (enExample)
BR (1) BR0214564A (enExample)
CA (1) CA2468839A1 (enExample)
HU (1) HUP0402401A2 (enExample)
MX (1) MXPA04005207A (enExample)
NO (1) NO20042730L (enExample)
NZ (1) NZ532562A (enExample)
WO (1) WO2003047697A2 (enExample)
ZA (1) ZA200403737B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498982A1 (en) * 2002-07-24 2004-01-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
AU2004289256A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer
AU2005216898A1 (en) * 2004-02-26 2005-09-09 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
WO2007042465A2 (en) * 2005-10-07 2007-04-19 Novartis Ag Combinati0n of nilotinib with farnesyl transferase inhibitors
JP2010507662A (ja) * 2006-10-25 2010-03-11 シェーリング コーポレイション 癌の処置のための不連続方法
EP2088862A4 (en) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd METHOD OF TREATING CANCER
EP4615842A1 (en) 2022-11-09 2025-09-17 Merck Patent GmbH Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
CZ298511B6 (cs) * 1997-12-22 2007-10-24 Schering Corporation Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
JP5491681B2 (ja) * 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
EP1267848B1 (en) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
WO2001064199A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
BR0114430A (pt) * 2000-10-05 2004-01-06 George Q Daley Processos para a indução da morte de células cancerìgenas e para a regressão de tumor

Also Published As

Publication number Publication date
CN101181269A (zh) 2008-05-21
NO20042730L (no) 2004-06-29
WO2003047697A3 (en) 2003-10-30
ZA200403737B (en) 2005-05-23
BR0214564A (pt) 2004-11-09
MXPA04005207A (es) 2004-08-19
US20030185831A1 (en) 2003-10-02
HUP0402401A2 (hu) 2005-03-29
CN1617755A (zh) 2005-05-18
EP1448268A2 (en) 2004-08-25
NZ532562A (en) 2007-02-23
CA2468839A1 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
WO2003047697A2 (en) 2003-06-12
US20060183765A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
Rudin et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
EP1622619B1 (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
Mayer et al. Chemotherapy for metastatic breast cancer
CN104997808A (zh) 用于治疗癌症的方法和组合物
JP2011522773A5 (enExample)
JP2003533485A5 (enExample)
TW200533339A (en) Therapeutic synergy of anti-cancer compounds
JP6898329B2 (ja) 併用療法
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
KR20090040926A (ko) 암 치료용 배합 생성물
JP2021505548A (ja) 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるｐａｒｐ阻害剤の使用
TW200404532A (en) Therapeutic combinations of ERB B kinase inhibitors and antineoplastic therapies
HK1248539A1 (zh) 借助塞里班土单抗的组合治疗
JP2005511663A (ja) 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用
JP2005511663A5 (enExample)
Wulkersdorfer et al. Pharmacokinetic aspects of vascular endothelial growth factor tyrosine kinase inhibitors
EP3969001A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
Saint-Ghislain et al. Adverse events of targeted therapies approved for women's cancers
Haglof et al. Recent developments in the clinical activity of topoisomerase-1 inhibitors
MX2007013830A (es) Terapia de combinacion.
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
AU2007201079A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents
JP2021508699A (ja) トリプルネガティブ乳がんを処置するためのｐｄ−１抗体及びアパチニブの併用処置の使用
KR20050116166A (ko) 이리노테칸의 저항성 유방암 치료용 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051122

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080722